Please use this identifier to cite or link to this item: https://doi.org/10.1182/blood-2011-07-367326
Title: Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias
Authors: Nicolini, F.E.
Basak, G.W.
Soverini, S.
Martinelli, G.
Mauro, M.J.
Müller, M.C.
Hochhaus, A.
Chuah, C. 
Dufva, I.H.
Rege-Cambrin, G.
Saglio, G.
Michallet, M.
Labussière, H.
Morisset, S.
Hayette, S.
Etienne, G.
Olavarria, E.
Zhou, W.
Peter, S.
Apperley, J.F.
Cortes, J.
Issue Date: 17-Nov-2011
Citation: Nicolini, F.E., Basak, G.W., Soverini, S., Martinelli, G., Mauro, M.J., Müller, M.C., Hochhaus, A., Chuah, C., Dufva, I.H., Rege-Cambrin, G., Saglio, G., Michallet, M., Labussière, H., Morisset, S., Hayette, S., Etienne, G., Olavarria, E., Zhou, W., Peter, S., Apperley, J.F., Cortes, J. (2011-11-17). Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood 118 (20) : 5697-5700. ScholarBank@NUS Repository. https://doi.org/10.1182/blood-2011-07-367326
Abstract: T315I + Philadelphia chromosome-positive leukemias are inherently resistant to all licensed tyrosine kinase inhibitors, and therapeutic options remain limited.We report the outcome of allogeneic stem cell transplantation in 64 patients with documented BCR-ABL T315I mutations. Median follow-up was 52 months from mutation detection and 26 months from transplantation. At transplantation, 51.5% of patients with chronic myeloid leukemia were in the chronic phase and 4.5% were in advanced phases. Median overall survival after transplantation was 10.3 months (range 5.7 months to not reached [ie, still alive]) for those with chronic myeloid leukemia in the blast phase and 7.4 months (range 1.4 months to not reached [ie, still alive]) for those with Philadelphia chromosome-positive acute lymphoblastic leukemia but has not yet been reached for those in the chronic and accelerated phases of chronic myeloid leukemia. The occurrence of chronic GVHD had a positive impact on overall survival (P ∇ .047). Transplant-related mortality rates were low. Multivariate analysis identified only blast phase at transplantation (hazard ratio 3.68, P ∇ .0011) and unrelated stem cell donor (hazard ratio 2.98, P ∇ .011) as unfavorable factors. We conclude that allogeneic stem cell transplantation represents a valuable therapeutic tool for eligible patients with BCR-ABL T315I mutation, a tool that may or may not be replaced by third-generation tyrosine kinase inhibitors. © 2011 by The American Society of Hematology.
Source Title: Blood
URI: http://scholarbank.nus.edu.sg/handle/10635/124782
ISSN: 00064971
DOI: 10.1182/blood-2011-07-367326
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.